TARRYTOWN, N.Y., April 29, 2019 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management
presentations as follows:
- Bank of America Merrill Lynch 2019 Healthcare Conference at
8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) on Wednesday, May 15, 2019
- Barclays 2019 Biopharmaceuticals CEO/CFO Conference Call Series
at 11:00 a.m. Eastern Time on Friday,
May 17, 2019
- UBS 2019 Global Healthcare Conference at 10:00 a.m. Eastern Time on Monday, May 20,
The sessions may be accessed from the "Investors &
Media" page of Regeneron's website at
Replays of the conference call and webcasts will be archived on the
Company's website and will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for 30 years by physician-scientists, our unique
ability to repeatedly and consistently translate science into
medicine has led to seven FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, neuromuscular
diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, such as
VelocImmune® which produces optimized fully-human
antibodies, and ambitious research initiatives such as the
Regeneron Genetics Center, which is conducting one of the largest
genetics sequencing efforts in the world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
SOURCE Regeneron Pharmaceuticals, Inc.